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Abstract 
Extra-intestinal manifestations (EIMs) of inflammatory bowel disease occur frequently and contribute 
to the morbidity and reduced quality of life in patients with inflammatory bowel disease (IBD). The 
musculoskeletal, ocular and cutaneous organ systems are frequently involved in IBD-related EIMs By 
focusing on manifestations involving the joints, skin and eyes, this review will discuss the most 
common, clinically relevant and burdensome EIMs that affect IBDpatients and strives for early 
recognition, adequate treatment and timely referral. For this purpose, we aimed to create a 
comprehensive overview on this topic with a main focus on the treatment of reactive and associated 
EIMs, including spondyloarthropathies, pyoderma gangrenosum, erythema nodosum, psoriasis and 
anterior uveitis. The recently developed biologicals enable simultaneous treatment of inflammatory 
disorders. This review can be used as a helpful guide in daily clinical practice for physicians who are 
involved in the treatment of IBD patients. 
Keywords 
Inflammatory bowel disease, Crohn’s disease, ulcerative colitis, extra-intestinal manifestation, ocular 
manifestation, musculoskeletal manifestation, cutaneous manifestation, treatment, therapy 
List of abbreviations 
5-ASA   5-aminosalicylicacid / mesalamine 
AP  Anteroposterior 
AS  Ankylosing spondylitis  
ASAS  Assessment of Spondyloarthritis International Society 
CD   Crohn’s disease 
COX  Cyclooxygenase 
CRP  C-reactive protein 
EIM(s)   Extra-intestinal manifestation(s) 
EN   Erythema nodosum 
HLA-B27 Human leucocyte antigen-B27 
HS   Hidradenitis suppurativa 
IBD  Inflammatory bowel disease 
IL  interleukin 
JAK  Janus kinase 
MTX  Methotrexate 
MRI  Magnetic resonance imaging 
NSAIDs  Non-steroidal anti-inflammatory drugs  
SpA   Spondylarthritis 
TNF  Tumor necrosis factor 
PASI  Psoriasis Area and Severity Index 
PGA  Physician Global Assessment 
PG  Pyoderma gangrenosum 
PSC   Primary sclerosing cholangitis 
PUVA  psoralen plus ultraviolet 
QoL  Quality of life 
RCT  Randomized controlled trial 
SI  Sacroiliac 
UC  Ulcerative colitis 
US  Ultrasound 
UST  Ustekinumab 
UVB  Ultraviolet B 
VDZ  Vedolizumab 
 
Clinical case 
A 45-year old woman with a history of ulcerative colitis (UC) since 1999, presents with complains of 
bloody diarrhea and pain in her left lower abdomen. Her dose of oral mesalamine is increased and 
topical mesalamine is started.  Concomitantly, she complains about new onset joint pain in both 
ankles and her right wrist. During physical examination, one light-red bruise on her right shin is 
visible, explained by herself as an injury due to a bicycle accident.  
Introduction 
Inflammatory bowel diseases (IBD) consist of Crohn’s disease (CD) and ulcerative colitis (UC). They 
are characterized by a chronic relapsing and remitting disease course that results in intestinal 
symptoms, but frequently also in extra-intestinal symptoms (EIMs) 1, 2. The latter can contribute to 
morbidity in IBD patients and can significantly reduce quality of life (QoL) 3, 4.  
The term EIM covers all IBD-associated clinical manifestations located outside of the gastrointestinal 
tract 1, 2. Based on the underlying pathophysiological and immunological mechanisms, EIM can be 
categorized into different, but sometimes overlapping, groups 1 (Table 1). The most common group, 
and main topic of this review, is the group of reactive manifestations. This group most likely shares 
pathophysiology with IBD, but has different histological appearances. Reactive manifestations may 
follow the intestinal disease course or become manifest independent of intestinal disease 1, 5, 6. Most 
frequently involved are the musculoskeletal, cutaneous and ocular organ systems. Extra-intestinal 
disease complications are directly related to the intestinal disease activity or to disease specific 
treatment and include for example osteoporosis, malnutrition, kidney- and gallstones and IBD-drug-
related symptoms 1, 2, 5-9. Associated diseases are less directly related to IBD compared to reactive 
EIMs, but are moredistinctive diseases that are frequently observed in the IBD population and that 
might share similar genetic and immune-mediated pathways 1, 6. Examples include axial 
spondylarthritis (SpA) including its archetype ankylosing spondylitis (AS), also known as Bechterew’s 
disease or radiographic axial spondyloarthritis, primary sclerosing cholangitis (PSC), psoriasis and 
hidradenitis suppurativa 1. A closely related or specific IBD manifestation, also called metastatic CD, 
shares the same histopathology as IBD and can be distinguished as a mucocutaneous form of CD 
specified as non-necrotizing granulomas at other sites than the gastrointestinal tract 9, 10. Urogenital 
(vulvar) and non-genital involvement (cutaneous/ nasal ulcerations, nodules or plaques) are 
examples of this rare manifestation 1, 8, 10.  
In general, 30-50% of IBD patients experience at least 1 EIM 5, 7, 11-15, with an over-all higher incidence 
in CD 5, 7, 11, 13, 16, 17, females 7, 13, 16, 17 , smokers 7, 16, 18, 19 and prolonged disease duration 17, 19. The 
presence of 1 EIM comes with a higher probability for developing other EIMs 5, 11, 16, 20. The majority of 
EIMs become manifest after establishing a diagnosis of IBD whereas uveitis and peripheral and axial 
arthritis precede the IBD-diagnosis in respectively 50%, 20% and 40% of patients 7, 11, 16.  
The presence of EIMs, and reactive EIMs in particular, is still underreported by gastroenterologists 
due to lack of awareness, time or diagnostic hurdles, and sometimes overreported by patients. Also, 
IBD patients themselves are often not aware of the possible relation between their extra-intestinal 
complaints and their bowel disease, so maynot report these complaints to their treating physician. In 
this narrative review we will answer clinically relevant questions about the most commonly observed 
EIMs to broaden the current knowledge about the occurrence, clinical picture, management and 
referral strategies.  
Method/ Literature search: 
We performed a Pubmed search with the following MESH, Majr and tiab terms: inflammatory bowel, 
Crohn, Chron’s, ulcerative colitis, pyoderma gangrenosum, erythema nodosum, episcleritis, uveitis 
anterior, scleritis, spondyloarthritis, spondyloarthropathies, ankylosing spondylitis, sacroiliitis, 
arthralgia, spondylitis ankylosing, extraintestinal manifestation, eye diseases, ocular manifestation, 
ophthalmic manifestation, eye manifestation, skin diseases, skin manifestation, dermatological 
manifestation, dermatologic manifestation, arthralgia, joint, back pain. 
The total search was limited to the publication date within the last ten years at time of search 
(January 2020). This search revealed 1184 publications. We excluded 573 papers for the following 
reasons including unavailable in English language, less useful type of research (case control studies), 
limited relevance of research questions or main outcomes (other diseases, not IBD-related) and other 
study population (children). After removing 68 duplicates, 315 articles (27.2%) were identified that 
met our inclusion criteria. The 228 articles left were scored as ‘maybe-useful’ while having other 
research questions of interests but could be used to ascertain relevant references. Via the snowball 
method we found the original and more recently published papers useful for this review.  
Clinical case continued 1 
Following the start of IBD therapy, the patient complains of less severe but long-term lower back 
pain, morning stiffness for at least 1 hour and which improves by movement and exercise. In 
addition, stiffness in both wrists and fingers does not allow for daily activities such as opening jars 
and holding cups. There is no visible swelling or redness. What is the differential diagnosis here and 
what treatment options are available? 
 
Musculoskeletal manifestations 
What are the different types of arthropathies associated with IBD? 
Arthropathies, an over-arching term for all types of joint disorders, can be classified according to the 
predominant localization of symptoms (axial or peripheral) and according to the presence or absence 
of clinical joint inflammation, called inflammatory arthritis 21-23. Moreover, it is important to place 
arthropathies in the context of active or quiescent IBD as this determinates the (treatment) 
approach24. Of note, in Anglo-Saxon countries the term arthritis is often used to cover also non 
inflammatory joint issues, hence the redundant term ‘inflammatory arthritis’. The term clinical is 
important,as in the absence of clinical features of inflammation and in non-inflammatory arthritis 
such as osteoarthritis (term for degenerative joint disorder), subclinical inflammation can sometimes 
be demonstrated using imaging (ultrasound (US), radiographic and magnetic resonance imaging 
(MRI)) without having clinically relevant consequences21, 25, 26. 
with.  
Inflammatory arthritis usually presents with signs of host response including synovial swelling, 
thickening and/or hydrops with symptoms like pain, stiffness, warmth and sometimes redness 21. 
Inflammatory joint complaints (also known as clinically suspect arthralgia), is defined as patient-
reported joint pain during the previous year, with stiffness of 1 hour or longer in the morning or after 
rest, improving upon on exercise, without presence of arthritis yet 21-23. More specific criteria exist if 
for example rheumatoid arthritis has been suspected as underlying disease for clinically suspected 
arthralgia 27. 
Arthritis can occur axially, mainly in sacroiliac (SI) joints and/or facet joints of the vertebrae. Arthritis 
in these joints lead to alternating buttock pain (sacroiliitis) and inflammatory backpain 
(spondylarthritis). Inflammatory backpain has been operationalized as morning stiffness, 
improvement upon exercise, no improvement upon rest and pain at night expressed before the age 
of 45 years (being aware that immunosuppressives suppress and thereby postpone inflammatory 
symptoms) 2, 21, 26, 28, 29. Arthritis in peripheral joints can be subdivided in monoarthritis or 
oligoarthritis including the involvement of respectively one or less than five joints and polyarthritis 
including the involvement of five or more joints 16, 23, 24. 
It is important to appreciate that both peripheral and axial arthritis are relatively rare conditions, 
whereas unspecific or mechanical joint or back pain are very prevalent in the general population as 
well as in IBD patients, and this large difference in a priori risk should be taken into account when 
assessing a patient. 
Clinical inflammatory arthritis 
If arthritis – either peripheral or axial - is present, this can be diagnosed as IBD-related arthritis, and 
this syndrome is categorized in the group of spondylarthritis (SpA), a broad term that covers 
interrelated inflammatory articular diseases in which axial as well as peripheral joints can be involved 
8, 25, 26, 30 . Of note, arthritis in IBD can of course also be due to sporadic unrelated other forms of 
inflammatory arthritis, like rheumatoid arthritis or gout. 
In general, around 8 % of IBD patients are diagnosed with SpA, of which 2-4% represents axial SpA 16, 
25. In peripheral SpA, arthritis can be present in all joints other than the spinal/axial joints, and also 
includes the rarer entities like enthesitis and dactylitis. 3, 7, 11, 16, 23, 25, 31 . In enthesitis, the inflammation 
affects the insertion of a tendon to the bone , most frequently seen in the Achilles tendon or plantar 
fascia at the calcaneus. 16, 22, 25 . In dactylitis, extended inflammation of the entire finger or toe results 
in a typical sausage-like appearance 25, 26. Axial SpA includes inflammation of the SI-joints, and the 
subtype AS 7, 13, 15, 16, 23, 25. The latter manifests itself in various ways including spondylodiscitis and 
sacroiliitis and sometimes with concomitant peripheral SpA features 22, 23, 25, 26. Rheumatologists use 
the so-called assessment of spondyloarthritis international society (ASAS)-criteria to classify both 
axial and peripheral SpA (see supplementary figure 1 adapted from Rudwaleit et al., 2011), however 
we will not discuss these criteria as their utility is limited for the IBD-population 1, 3, 22, 28, 29.  
Non-inflammatory joint complaints 
Non-inflammatory joint complaints, also called unspecific joint pain, arthralgia or arthropathy, can be 
defined as joint pain in the absence of clinical inflammatory arthritis. It is often seen as a diagnosis of 
exclusion and includes the ‘regular’ most common types of joint pain like osteoarthritis and other 
mechanical causes of joint pain, frequently reported in the elderly population or in patients with 
physically demanding jobs 16, 21, 26. It is important to realize that the initiation (e.g. anti-tumor necrosis 
factor (-TNF) agents, vedolizumab (VDZ), ustekinumab (UST)) or withdrawal (e.g. corticosteroids) of 
certain drugs can also trigger joint pain 8, 14, 26, 32-35 .  
How can we differentiate inflammatory arthritis from non-inflammatory joint complaints? 
First of all, when septic arthritis or spondylodiscitis are suspected urgent referral is important. This is 
in case of acute onset of back pain or joint swelling in one or a few joints (monoarthritis or 
oligoarthritis), accompanied by fever and elevated inflammatory parameters 21. In less acute 
scenarios, it can be difficult to make a distinction between non-inflammatory and inflammatory joint 
disease in IBD, as joint complaints can be seen as spectrum starting from unspecific joint pain (or 
arthralgia) without suspected inflammation, via clinically suspected arthralgia with symptoms 
indicating (imminent) arthritis,  eventually to a clearly observed and diagnosed clinical inflammatory 
arthritis (SpA). Because of these difficulties, referral to a rheumatologist is required to rule out or 
confirm the presence of inflammation and if indicated perform further investigations to establish a 
clear diagnosis 21, 22, 28.  
Physical examination can reveal signs of inflammation including visible redness, palpable warmth and 
tender joints or tendon insertion-areas and absence of the normal joint cleft during palpation 21. In 
contrast to other causes of peripheral arthritis such as rheumatoid arthritis, peripheral SpA in IBD 
often displays an asymmetrical distribution 21-23, 26. Subtle signs of inflammation can be difficult to 
recognize and therefore physical examination of the joints is often performed by a rheumatologist. 
Laboratory results are often not sensitive and specific enough and it is advised to consult a 
rheumatologist before ordering HLA-B27 or specific rheumatological antibodies tests. US can be used 
to detect effusion of the synovial fluid in enthesitis or arthritis, but this technique is not performed 
on regular basis as its interpretation can be difficult 26, 36 .  
Of note, for identification of SpA in uveitis patients or psoriasis patients, validated diagnostic tools 
are available for triage but for IBD, these have not been developed yet. Overall, for establishing a 
diagnosis in IBD patients with joint complaints, physical examination and imaging techniques are 
most valuable when performed by a rheumatologist. A stepwise referral strategy for IBD patients 
with unexplained joint complaints is still missing, therefore a suggested clinical algorithm has been 
designed to help gastroenterologists in this decision-making process (Figure 1).  
How to approach joint symptoms in IBD patients? 
In contrast to non-inflammatory joint complaints, it is important to recognize and treat axial and 
peripheral SpA in an early stage to prevent pain, additional symptoms, function loss and 
inflammation 2, 22, 26, 31. It is advised to refer an IBD patient with chronic low back pain (at least 3 
months) with an insidious onset, before the age of 45 years, morning stiffness (persistent about 1 
hour), with good effect of exercise and/or with peripheral joint pain or swelling or with the presence 
of dactylitis or enthesitis to a rheumatologist in order to diagnose and treat SpA 8, 16, 21, 28, 37. As it is 
difficult to distinguish peripheral SpA in IBD from other underlying causes of peripheral arthritis, it is 
advised to consult a rheumatologist in case of arthritis or clinically suspect arthralgia, in particular 
with the concomitantly presence of psoriasis, anterior uveitis or a positive familiar history of SpA21, 28, 
37. As both inflammatory and non-inflammatory types of joint complaints have a great impact on the 
QoL of IBD patients, they all require early recognition and an adequate treatment approach 3, 4 . Head 
to head strategy studies about the therapeutic approach are still missing and current literature often 
takes arthralgia together with arthritis without differentiating in the subdivisions used below 38. We 
as research group previously reported on real-live registered data about IBD patients using newer 
therapies including UST and VDZ in IBD patients and , similar to other studies,  both seem effective to 
treat IBD patients with arthralgia/arthritis 21, 32. Conflicting evidence about VDZ and UST causing 
(paradoxical) arthralgia 14, 33, 34, could be explained by the fact that during induction-phase of VDZ and 
UST, steroids are often simultaneously tapered that causes an increase of joint complaints.  
Randomized controlled trials are needed to clarify on this topic.  
Axial SpA 
Sulfasalazine, methotrexate (MTX) nor thiopurines seem effective to treat axial SpA8, 21, 24, 26, 39 . 
However, mesalamine should be maintained for UC-patients to remain remission and for the possible 
role in prevention of colorectal cancer and thiopurines can also be maintained as combined 
therapeutic option for immunomodulator naïve CD-patients 24.  
Active IBD 
First choice to treat axial SpA in active IBD are anti-TNF agents 8, 12, 24, 26. In case of non-response, 
either the dose can be increased, the interval shortened or anti-TNF agent can be switched to 
another 24. In case axial SpA is in remission, continuing with adalimumab has been advised as the risk 
of recurrence after treatment cessation seems high, however ongoing research is conflicting and the 
evidence is inconclusive yet  24, 40. 
IBD in remission 
When IBD is in stable remission, short-term use (less than 2 weeks) of NSAIDs including selective-
COX-2-inhibitors are an option, but there should be a low threshold to start anti-TNF agents to 
prevent complications of ongoing axial SpA, especially if anti-TNF agents previously had a positive 
effect on the intestinal disease activity8, 12, 24, 26. Third line therapeutic options includes ustekinumab 
(interleukin, IL-12 and 23-inhibitor) or janus kinase- (JAK-) inhibitors (tofacitinib) 41. 
Peripheral SpA 
Active IBD  
Effective therapies for oligoarthritis and polyarthritis are local steroid injection, low dose of systemic 
steroids or sulfasalazine (2g/day or 4g/day respectively)  whereas the effectiveness of the latter 
remains inconclusive 8, 24, 26, 35, 39. In IBD, preferred therapy for both intestinal and peripheral joint 
inflammation could be sulfasalazine in mild IBD (whereas topical mesalamine should be maintained 
in distal active UC)and systemic steroids, immunomodulators, anti-TNF agents (infliximab and 
adalimumab) or tofacitinib in moderate-to-severe IBD 12, 24, 26, 35, 38, 41.  
IBD in remission 
Similar to axial SpA, for both oligoarthritis and polyarthritis short-term use of selective 
cyclooxygenase (COX)-2-inhibitors are accepted in inactive IBD, preferably used to bridge local 
injections of steroids in oligoarthritis and oral sulfasalazine therapy (2-3g/day) for polyarthritis 24, 26, 
35. In case of non-response, anti-TNF agents are safe second therapeutic options 24, 35, 38. 
Non-inflammatory arthralgia 
For non-inflammatory joint complaints treatment options are generally limited to physical therapy 
and/or a stepwise approach of analgesics starting with acetaminophen (though not effective in 
osteoarthritis), and adding COX-2-inhibitors (such as etoricoxib or celecoxib) as second step 21, 26. In 
case of osteoarthritis, in some cases referral to an orthopedic surgeon is indicated and helpful 21.  
In table 2 an overview of all above mentioned therapeutic options for musculoskeletal 
manifestations in IBD patients have been summarized.   
Are non-steroidal anti-inflammatory drugs (NSAIDs) safe for IBD patients? 
The use of NSAIDs in IBD, especially the ones with relative high selectivity for COX-1-inhibition, is 
usually discouraged because of the possible risk of an exacerbation of the underlying IBD 8, 26, 35. 
Generally, a selective COX-2-inhibitor is preferred as a safer alternative 8, 26, 44. However, evidence 
about the effect of conventional (COX -1)-inhibitors on intestinal disease activity is conflicting as 
some studies found early clinical relapses right after the start of NSAIDs 45, whereas other studies did 
not find a clear association between NSAIDs and the risk of intestinal exacerbation 46. It is generally 
believed that COX-2-inhibitors have a reduced likelihood to induce intestinal flares compared with 
COX-1-inhibitors, however these somewhat older studies are based on less used COX-2-inhibitors or 
compared COX-2-inhibitors with placebo rather than COX-1-inhibitors 44, 45, 47. In short, evidence on 
this topic is inconsistent and based on older and heterogenic studies, so further research will be 
necessary to find out more about safe use of different types of NSAIDs. Awaiting further research on 
this topic, use of selective COX-2 inhibitors is the preferred strategy while short-term treatment with 
relative COX-1-selective NSAIDs might be a safe alternative if the underlying IBD is in remission 8, 21, 26, 
30, 35, 46, 47. 
 
 
Clinical case continued 2 
After a week she develops more red-colored painful lesions located on the anterior surface of the 
right tibia. Based on the typical clinical features, she is diagnosed with erythema nodosum and a 
short course of low-dose prednisone is started. Within 3-4 weeks the nodules have completely 
resolved without scar formation. The joint pain in her ankles and knees simultaneously disappeared. 
Cutaneous manifestations 
How to differentiate cutaneous manifestations in IBD patients?  
In general, about twenty percent of IBD patients at some time point report concomitant skin 
disorders. Given the extensive differential etiology for skin lesions, we will discuss here four 
diagnoses with specific clinical relevance in IBD patients. With a prevalence ranging from 1-15% in 
IBD- patientserythema nodosum (EN) is the most common particular in CD-patients (7-15%) 
(compared with 2.8-10% in UC-patients) 5, 7, 11, 13, 15, 17, 19, 48. Pyoderma gangrenosum (PG) is a rare EIM, 
occurring in only 0,8 -5% of  IBD patients, and in contrast to other EIMs, PG is more common in UC 
(0.9-8%) than CD (0.7-3.5%), and has potentially severe impact on QoL 5, 7, 11, 13, 15, 17, 19, 49. Another 
important skin disorder to take into account is hidradenitis suppurativa (HS or also called acne 
inversa), generally considered as a distinctive (or IBD-associated) disease, but with a prevalence of up 
Key points inflammatory joint complaints in IBD 
 Rule out septic arthritis first and use history, physical examination , laboratory results 
and imaging techniques to differentiate 
 Strive for a multidisciplinary treatment approach together with a rheumatologists and 
consider drugs that simultaneously treat IBD and joints:  
 Axial SpA and active IBD: anti-TNF agents are first choice 
 Axial SpA and IBD in remission: short-usage of COX-2-inhibitors, anti-TNF agents in non-
responders 
 Peripheral SpA and active IBD: in mild IBD, local steroids injection, sulfalasazine, low-
dose steroids. In moderate-to-severe IBD, anti-TNF agents.  
 SpA and quiescent IBD: short-term use of selective COX-2-inhibitors, sulfalasazine and in 
non-responders an anti-TNF agents 
Key points non-inflammatory joint complaints in IBD 
 Diagnosis of exclusion which can be IBD-related or can have various alternative 
underlying causes (degenerative, mechanic, therapeutic side- effects or withdrawal-
induced) 
 Treatment:physical therapy , COX-2-inhibitors (which are preferred over COX-1-inhibitors 
in particular for long-term use)  
to 23% in IBD patients (0.4-15% in CD and 0.1-6.1% in UC) compared to 0,1-4% in the general 
population 7, 50-52. Psoriasis has been seen as an associated disease with IBD and occurs in 2.7-8.3% of 
the IBD patients with a higher prevalence in CD (2.8-3.3%) than in UC (2.1-2.9%) 7, 11, 15, 53. 
EN is characterized by painful, slightly raised, subcutaneous red-violet nodules of 1-5 cm in diameter 
and located on extensor surfaces of the lower extremities (anterior tibia) (Figure 2) 8. EN can be 
triggered by a broad range of underlying conditions, like other inflammatory diseases (e.g. 
Sarcoidosis), infections (Streptococcus, Tuberculosis), malignancies, drugs (sulphonamides, 
contraceptive pills) or pregnancy 2, 9. In EN, skin biopsies are seldomly required because of the very 
typical clinical picture of the lesions 8. 
PG has different subtypes but in the most common classic form, which is the ulcerative variant, PG 
starts with a (painful) erythematous nodule or plaque, sometimes with small erythematous sterile 
pustules. Consecutively necrotic ulcerative areas with violaceous irregular edematous edges develop 
which can rapidly extend to surrounding areas 8. The ulcers contain sterile purulent material, vary in 
size from 2-20 cm in diameter and can be the source of development of superinfections or sepsis 8, 49. 
Most common localizations of PG are the lower legs (pretibial) and peristomal areas (Figure 2), up to 
80% and 18% respectively, but PG can appear anywhere on the body surface 49, 54. PG as an ulcerative 
disorder has a broad differential diagnosis, which can be subdivided into vascular (venous, arterial, 
occlusive or vasculitis) diseases, hematological diseases (polycythemia vera), malignancies, infections 
and drug-induced tissue injury 54, 55. In PG, infectious causes can be ruled out by skin swabs of the 
ulcerative lesions. Biopsies often show an unspecific neutrophilic infiltration and necrosis, also signs 
of vasculitis can be seen. Biopsies are preferred over skin swabs to rule out other kinds of underlying 
diseases including malignancy 2, 8, 55-57. This has to be done with caution as a typical phenomenon 
called pathergy can occur after a preceding trauma and can often contribute to the expansion of PG 
lesions 49, 54, 56.  
In HS, the diagnosis is often established by lesion morphology, location and lesion progression rather 
than skin biopsies 58. HS is characterized by recurrent formation of painful inflamed skin lesions, 
developing abscesses and interconnected sinus tracts mainly at inverse body regions, like the 
inguinal, axillary and peri-anal area (Figure 2) 10, 50, 51, 58. In HS, the diagnostic process can be delayed 
because HS sometimes resembles a simple skin infection or carbuncles/furuncles in an early stage 
and besides, HS in peri-anal regions can sometimes be hard to distinguish from peri-anal fistulas in 
Crohn’s disease 50, 52, 58.  
Of the different forms of psoriasis, psoriasis vulgaris or the chronic plaque psoriasis, is the most 
common subtype 59, 60. Psoriasis vulgaris is characterized by the presence of clearly defined 
monomorphic erythematous plaques with silver-coloured gill-like scales 59, 60. Psoriasis is commonly 
localized at extensor areas of elbows, knees, scalp, peri-umbilical and peri-anal areas 59. Flexural (skin 
folds) areas, nails, scalp and joints (psoriatic arthritis) can be involved, the latter in up to 30% of 
patients with moderate-to-severe psoriasis 59 
Other subtypes of psoriasis can manifest as sterile pustules instead of plaques 59. Psoriasis can be 
triggered by mild trauma, systemic drugs or infectious diseases (HIV) 59. Specific scoring-systems for 
disease activity are used such as PASI (Psoriasis Area and Severity Index) or PGA (Physician Global 
Assessment) 59, 61. Other cutaneous diseases could give difficulties in establishing the diagnosis 
including tinea pedis or corporis, seborrheic dermatitis or eczema 59.An important form of psoriasis is 
so-called paradoxical psoriasis, which can be induced by treatment with anti-TNF agents, especially 
infliximab and adalimumab 38, 53, 59, 60. Paradoxical psoriasis is clinically very similar to classic psoriasis 
but its inflammatory pathway is different and is dominated by interferon type 1 60. Treatment is 
difficult and often withdrawal of the drug that caused this type is necessary 60. 
How to approach cutaneous manifestations in IBD patients? 
In IBD patients with EN, the most likely trigger is intestinal disease activity of the underlying IBD and 
adequate treatment of the IBD will frequently lead to resolution of EN without scar-formation 7, 12, 38. 
In case of refractory EN or when in doubt, referral to a dermatologist can be helpful to establish a 
definite diagnosis. In severe cases where lesions can be very painful, a short course of oral 
corticosteroids (0.5-1mg/kg/day during 1 or 2 weeks) usually leads to rapid resolution of EN 8, 9. In 
collaboration with a dermatologist hydroxychloroquine can be a second line therapy.  
If PG is suspected, the diagnosis and treatment should take place in close collaboration with a 
dermatologist as PG has an unpredictable and damaging disease course due to pain, frequent 
recurrences, scarring, secondary infections and even sepsis  9, 49. Delay in recognition and treatment 
can lead to progression of the lesion and subsequent complications 55, 56. In case intestinal disease 
activity is present, treating the underlying IBD often results in improvement of PG 5, 38, 49. Important in 
the treatment of PG are wound care, pain management and exclusion of skin infections before 
initiating immunosuppressants. Surgical interventions (excision) should be avoided if possible as 
traumas may worsen PG lesions 9. In mild cases topical therapy can be used such as corticosteroids or 
topical tacrolimus 9, 49. In moderate to severe cases systemic (oral) corticosteroids, e.g. prednisolone 
(0.5-2mg/kg/d), calcineurin-inhibitors such as oral tacrolimus (0.3mg/kg/d) or cyclosporine (4-5 
mg/kg/d) can be required 9, 49. To prevent longstanding use of corticosteroids, azathioprine and MTX 
are good alternatives as maintenance strategy for both PG and IBD in order to prevent recurrence. 
Anti-TNF agents, infliximab and adalimumab in particular, are very effective treatment options in 
case of delayed response to corticosteroids 38, 49, 57. Aggressive and prolonged therapy is required 
until the PG-lesions are completely healed 49. 
In general, factors associated with cutaneous manifestations are smoking and obesity and discussing 
these life style factors is particularly important as a first step in the treatment of patients with HS 19, 
51, 52.HS is notorious for its debilitating disease course and difficulties in treatment. Close 
collaboration with dermatologists and surgeons is advised to aggressively treat HS in order to 
prevent long-term inflammation, fibrosis and scarring 50, 58. To treat the inflammation, first choice in 
mild cases is topical clindamycin 58. Prolonged treatment with oral tetracycline, combination 
therapies consisting of multiple antibiotics, or treatment with acitretin can be considered in 
moderate to severe HS 50, 58. For single nodules, oral intralesional steroids could be effective 50, 58. 
Randomized controlled trials (RCT’s) showed that intravenous infliximab 5mg/kg and weekly 
subcutaneous adalimumab 40 mg (loading dose 160 mg) are effective therapies for moderate-to-
severe HS 62, 63. HS in IBD patients often follows a more severe disease course than in patients 
without IBD and in severe cases, early and surgical wide incision and drainage reduces the risk of 
recurrence from about 38.5 % to 8% 50, 58. 
In IBD patients with psoriasis or concomitant psoriatic arthritis, a multidisciplinary approach is 
advised together with the dermatologist and/or rheumatologist. Mild psoriasis can be treated with 
topical therapy including corticosteroids, derivatives of vitamin D and calcineurin inhibitors 
(tacrolimus) for sites with persistent disease activity 59. In moderate-to-severe psoriasis, 
phototherapy or photochemotherapy including narrow band Ultraviolet B (UVB) or psoralen plus 
Ultraviolet A (PUVA) respectively, are effective but often not enduring 59. Conventional systemic 
treatment includes methotrexate, cyclosporine, acitretin and fumaric acid esters 59, 61. Infliximab and 
adalimumab are effective to treat both IBD and psoriasis whereas other biologicals like IL-17 
inhibitors can affect the intestinal disease activity 59, 61. New biologicals, such as IL-23 antagonists are 
registered for psoriasis and may also be effective treatment for patients with IBD and psoriasis 64.  






Clinical case continued 3 
A few years later, the same patient calls the outpatient clinic because of a slightly painful eye 
combined with photophobia and pain. There is no redness of the eye. Her UC is in clinical remission 
under azathioprine and mesalamine.  
After immediate referral to an ophthalmologist, the patient is diagnosed with iridocyclitis, which is 
successfully treated with intraocular corticosteroids. 
 
How to differentiate reactive ocular manifestations in IBD? 
The most common ocular EIMs in IBD are episcleritis and anterior uveitis with a prevalence of 2-4% 
and 1.7-5% respectively whereas anterior uveitis seems more common in CD (1.5-11%) than UC (0.7-
Key points erythema nodosum 
 Clinical diagnosis with red-violet nodules typically located on the shins 
 In IBD: erythema nodosum mirrors the intestinal disease activity 
 Treatment: self-limiting, as soon as underlying IBD is adequately treated. Consider 
corticosteroids for rapid resolution of symptoms.  
Key points pyoderma gangrenosum 
 Diagnosis of exclusion, broad differential diagnosis 
 Treatment: mild cases with topical therapy, moderate to severe cases with systemic anti-
inflammatory therapy including corticosteroids, calcineurin inhibitors or anti-TNF agents 
Key points hidradenitis suppurativa 
 Unpredictable debilitating disease course with reduced QoL  
 Treatment: antibiotics, anti-TNF agents, surgery (deroofing) 
Key points psoriasis 
 Associated skin disease of IBD, can also manifest in the nails and joints (psoriatic arthritis) 
 Multidisciplinary approach: topical therapy calcineurin inhibitors, corticosteroids or 
photo(chemo)therapy or systemic therapy (anti-TNF agents or ustekinumab) 
10.5%)  7, 11-13, 15, 65, 66. With a prevalence of <1%, scleritis and other types of uveitis including 
intermediate and posterior uveitis, are less frequent 1, 15, 67. For an overview of the anatomy of the 
eye, see figure 3.  
In episcleritis, a benign and often recurrent inflammation of the episcleral causes acute redness, 
irritation, tearing and mild-to-moderate discomfort in one or both eyes 2, 68, 69. Episcleritis can be 
discriminated from scleritis or uveitis by the absence of visual impairment or ocular pain 8, 68. 
Episcleritis can sometimes be difficult to distinguish from conjunctivitis, which is a benign and often 
self-limiting disorder, as in both conditions hyperemia is  usually present 15, 20, 65, 69. 
Scleritis is characterized by deeply inflamed sclerae causing scleral edema 68. Typical features are the 
presence of severe ocular ache radiating to the scalp and face, that worsens at night and can cause 
visual loss 8, 69. In the most common type of anterior scleritis hyperemia is visible, which is often not 
the case in posterior scleritis 69 .  
In uveitis, inflammation of the middle layer of the eye (the uvea) can affect the iris, ciliary body and/ 
or choroid (Figure 3) 70. This may lead to one of four different types of uveitis: anterior, intermediate, 
posterior or pan-uveitis. Anterior uveitis is the most common type in IBD 1, 8, 65, 70. The symptoms 
depend on the localization of inflammation, but is mostly characterized by the presence of ocular 
pain, blurred vision, photophobia and headaches 2, 8, 65, 69. A typical feature of anterior uveitis is the 
presence of a so-called hypopyon which is formed by accumulation of inflammatory cells into the 
anterior eye chamber causing a visible pocket with pus 2, 70. 
 
 
How to approach ocular manifestations in IBD patients? 
In case of impaired vision and ocular pain rather than discomfort, there should be a strong suspicion 
of scleritis or uveitis and immediate referral to an ophthalmologist is necessary as both scleritis and 
uveitis can result in permanent visual loss if left untreated 1, 8, 65, 68, 69.  
As episcleritis often parallels the intestinal disease activity, it is important to control the underlying 
IBD 7. Episcleritis is mostly self-limiting and topical corticosteroids are rarely necessary 1, 2, 69. A wait-
and-see approach is advised. In case of doubt about the diagnosis or in case of the development of 
new and alarming symptoms, referral to an ophthalmologist is indicated. 
Treatment of scleritis and uveitis are usually carried out by an ophthalmologist. In case of scleritis 
topical anti-inflammatory agents such as dexamethasone eye drops or systemic corticosteroids are 
necessary and contribute to a good prognosis 2, 67, 68. In case of uveitis, in mild cases, topical 
corticosteroids may be sufficient but regularly (and in more severe cases), systemic corticosteroids,  
or anti-TNF agents are required 8, 38, 66.  
See table 2 for an overview of above mentioned therapies for ocular manifestations in IBD patients.  
 
Key points episcleritis 
 Common ocular manifestation in IBD, without ocular pain or vision impairment 
 In IBD: related with intestinal disease activity  




Evidence-based knowledge on the pathogenesis of EIMs in IBD is lacking and two theories cover most 
of the current theories 1. The first theory is that EIMs can be seen as disseminated immune affecting 
extra-intestinal localizations, caused by, for example, microbial antigenic cross-reactivity or 
translocation 1. This theory would imply that fecal transplantation or the usage of pre- or probiotics 
are potential targets for the treatment of EIMs. Research is ongoing and the evidence is yet 
inconclusive. In a second theory, the inflammatory events causing EIMs and those causing IBD are 
considered independent inflammatory entities provoked by similar environmental or genetical 
factors in susceptible patients 1, 30. From this point of view, the differences between reactive and 
associated EIMs in IBD can be explained. However, with the absence of stringent definitions of 
musculoskeletal manifestations and limited literature about ocular manifestations and erythema 
nodosum in IBD, more research is required to understand which pathways are involved and to 
improve the treatment approach. The latter is the biggest issue for gastroenterologists during their 
outpatient visits. And where Varkas et al.(2019) designed a useful stepwise treatment approach for 
musculoskeletal manifestations in IBD, golden standards for the treatment of EIMs in IBD and 
therapeutic options are still warranted and the questions (shown in supplementary figure 2) remain 
unanswered 21.  
Conclusion  
Almost half of IBD patients report EIMs of which musculoskeletal manifestations are the most 
common, followed by cutaneous and ocular manifestations. When coming across (suspected) EIMs 
during the treatment or follow-up of an IBD patient, close collaboration with rheumatologists, 
dermatologists and ophthalmologists is advised in order to prevent diagnostic delays and irreversible 
damage. A research agenda aimed at further elucidating the pathogenesis of EIM, and to establish 
evidence-based therapeutic approaches, is crucial to improve quality of life for IBD patients. 
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Key points scleritis 
 Rare ocular manifestation in IBD characterized by severe radiating ocular pain and 
impaired vision 
 Management: immediate referral to an ophthalmologist to prevent permanent loss of 
Key points uveitis 
 Of the four types of uveitis, anterior uveitis is the most common, characterized by ocular 
pain, photophobia and blurred vision 
 Treatment: urgent referral to an ophthalmologist, often treated with systemic 
corticosteroids, biologicals or anti-TNF agents 
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Figure legends 
1. Table 1:  
Overview of the different types of extra-intestinal manifestations in IBD patients. IBD: inflammatory 
bowel disease; EIM: extra-intestinal manifestations; SpA: spondylarthritis; CD: Crohn’s disease; anti-
TNF: anti-tumor necrosis factor 
2. Supplementary figure 1:  
ASAS- classification criteria for axial and peripheral SpA. Adapted from Rudwaleit et al.(2011) 22. 
ASAS: Assessment of Spondyloarthritis International society; SpA: Spondylarthritis; HLA-B27: Human 
leucocyte antigen-B27; CRP: C-reactive protein; IBP: inflammatory back pain 
3. Figure 1:  
Flowchart for gastroenterologists with suggested approach for the management of IBD-patients with 
joint complaints. NSAIDs: Non-steroidal anti-inflammatory drugs; X-ray: radiographic imaging 
technique ; MRI: Magnetic resonance imaging technique; COX: Cyclooxygenase.  
 
4. Table 2 
Overview of first, second and third line therapy of extra-intestinal manifestations in patients with 
inflammatory bowel disease. 
In all cases active intestinal disease activity, if present, should have priority in the management of 
extraintestinal manifestations. Suggested treatment are traded towards treatment of intestine and 
extraintestinal manifestation. 
COX: cyclooxygenase, EIMs: extraintestinal manifestations, IBD: inflammatory bowel disease, IL: 
interleukin, JAK: janus kinase, PG: pyoderma gangrenosum, SpA: spondylarthritis, TNF: tumor 
necrosis factor 
5. Figure 2:  
Cutaneous manifestations: erythema nodosum located on the anterior shin (a), peristomal pyoderma 
gangrenosum (b), pyoderma gangrenosum located at the lower leg (c), axillary hidradenitis 
suppurativa (d), psoriasis (e)  
Adapted from personal archive (a, b) and www.huidziekten.nl (c,d, e) 
6. Figure 3:  
Anatomic overview of the eye and ocular manifestations  
 
7. Supplementary Figure 2: 
Future perspectives. IBD: inflammatory bowel disease; EIM: extra-intestinal manifestations 
 
 
